M&As this week: Diasend AB, Atos SE, Venaxis

15 September 2016 (Last Updated September 15th, 2016 18:30)

With an aim to provide the best diabetes management platform, Diasend AB and Glooko, two companies well-known for diabetes management and analytics platforms, have announced a merger to form a unified company called Glooko.

With an aim to provide the best diabetes management platform, Diasend AB and Glooko, two companies well-known for diabetes management and analytics platforms, have announced a merger to form a unified company called Glooko.

The newly formed company will track the data from more than 160 diabetes management systems such as glucose meters, insulin pumps, continuous glucose monitors (CGMs) and activity trackers that constitute 95% of diabetes devices used across the globe.

The data will be used to serve more than 4,000 diabetes clinics in 23 countries during and in-between doctor visits, and in-office diabetes data uploads and analytics.

"The data will be used to serve more than 4,000 diabetes clinics in 23 countries during and in-between doctor visits."

In a move to further strengthen its digital health services portfolio in the US healthcare market, European IT services provider Atos SE intends to acquire Anthelio Healthcare Solutions, a leading healthcare technology company in North America, from Actis and McLaren Health Care Corporation, in a $275m cash deal.

The acquisition, which is anticipated to close on 30 September 2016, will enable Atos to provide improved patient care experience by addressing issues related to security, risk and compliance and by offering state-of-the-art applications for patient care.

In-vitro diagnostics developer, Venaxis, has completed the acquisition of BiOptix Diagnostics, which developed a proprietary enhanced surface plasmon resonance (E-SPR) technology platform to detect molecular interactions.

The former has acquired approximately 98% of the voting shares of the latter in exchange of 14% of its post-deal outstanding common shares.

The acquisition will leverage BiOptix’s technology and market opportunity coupled with Venaxis’ resources and public listing.